Meropenem Sun

Meropenem, the active ingredient in Meropenem Sun, is a carbapenem antibiotic presented as an injection solution for intravenous use. It treats a range of serious bacterial infections in hospitalized adults and children, including intra‑abdominal infections, urinary tract infections, pneumonia, meningitis and sepsis.

GNH USA supplies Meropenem Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global healthcare institutions. Our network ensures timely delivery and regulatory compliance across multiple regions.

Meropenem is a broad‑spectrum carbapenem antibiotic used for severe bacterial infections affecting various organ systems. - Complicated intra‑abdominal infections: achieves rapid bacterial eradication and clinical cure in patients with peritonitis or intra‑abdominal abscesses. - Complicated urinary tract infections: provides effective clearance of resistant Gram‑negative pathogens causing pyelonephritis and cystitis. - Nosocomial pneumonia: improves survival by targeting multidrug‑resistant organisms in hospital‑acquired lung infections. - Bacterial meningitis: penetrates the cerebrospinal fluid to eradicate causative bacteria and reduce mortality. - Severe sepsis and septic shock: delivers bactericidal activity essential for controlling systemic infection and organ dysfunction.

Meropenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in many patients. - Diarrhea: loose stools, occasionally leading to dehydration. - Vomiting: occasional emesis, especially with rapid infusion. - Headache: transient cranial discomfort. - Rash: mild skin erythema or pruritus. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Seizures: risk increased in patients with renal impairment or CNS disorders. - Severe allergic reactions: anaphylaxis or Stevens‑Johnson syndrome. - Clostridioides difficile colitis: antibiotic‑associated colitis leading to severe diarrhea. - Hemolytic anemia: rare immune‑mediated destruction of red blood cells. - Thrombocytopenia: low platelet count, potentially causing bleeding.

When using Meropenem, clinicians should observe several safety considerations to minimize risk. - Renal function: adjust dose in patients with impaired kidney function. - Allergy history: avoid in individuals with known hypersensitivity to carbapenems or β‑lactams. - Seizure risk: monitor closely in patients with central nervous system disorders or high doses. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Drug interactions: review concomitant medications for possible pharmacodynamic or pharmacokinetic effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: may significantly reduce plasma concentrations, risking loss of seizure control. - Probenecid: can increase meropenem levels, raising the potential for toxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: may enhance nephrotoxic potential, requiring renal function monitoring. - Aminoglycosides: additive nephrotoxicity and ototoxicity risk when used together. - Anticoagulants (e.g., warfarin): may alter INR, necessitating more frequent coagulation testing.